Maryland

Dr. Adinoff's written testimony on a Maryland bill that would cap THC at 15% in the adult-use market and would prevent individuals with a diagnosis of cannabis-induced psychosis from purchasing cannabis in either the medical or adult-use markets.

March 1, 2023

Dr. Deondra Asike provided her first written testimony as DFCR's new Maryland Spokesperson to the House Economic Matters Committee of the Maryland General Assembly in support of HB556 but suggesting several amendments which would further protect patient and consumer safety.

February 16, 2023